Literature DB >> 25769807

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

Russell W Jenkins1, Geoffrey R Oxnard1, Sheryl Elkin2, E Kelly Sullivan2, Jennifer L Carter2, David A Barbie3.   

Abstract

Entities:  

Keywords:  Crizotinib; Lung adenocarcinoma; MET; Splice site mutation

Mesh：

Substances：

Year:  2015        PMID： 25769807      PMCID： PMC4529392          DOI： 10.1016/j.cllc.2015.01.009

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  12 in total

1.  Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Authors:  Monica Kong-Beltran; Somasekar Seshagiri; Jiping Zha; Wenjing Zhu; Kaumudi Bhawe; Nerissa Mendoza; Thomas Holcomb; Kanan Pujara; Jeremy Stinson; Ling Fu; Christophe Severin; Linda Rangell; Ralph Schwall; Lukas Amler; Dineli Wickramasinghe; Robert Yauch
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

4.  Molecular cloning of a new transforming gene from a chemically transformed human cell line.

Authors:  C S Cooper; M Park; D G Blair; M A Tainsky; K Huebner; C M Croce; G F Vande Woude
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

Review 5.  MET signalling: principles and functions in development, organ regeneration and cancer.

Authors:  Livio Trusolino; Andrea Bertotti; Paolo M Comoglio
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12       Impact factor: 94.444

Review 6.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Authors:  Mark M Awad; Alice T Shaw
Journal:  Clin Adv Hematol Oncol       Date:  2014-07

7.  Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.

Authors:  Ryoichi Onozato; Takayuki Kosaka; Hiroyuki Kuwano; Yoshitaka Sekido; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

8.  Scatter factor/hepatocyte growth factor is essential for liver development.

Authors:  C Schmidt; F Bladt; S Goedecke; V Brinkmann; W Zschiesche; M Sharpe; E Gherardi; C Birchmeier
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

9.  Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.

Authors:  L Naldini; E Vigna; R P Narsimhan; G Gaudino; R Zarnegar; G K Michalopoulos; P M Comoglio
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

10.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962
View more
  30 in total

1.  MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors:  Thanyanan Reungwetwattana; Sai-Hong Ignatius Ou
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 2.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

Review 3.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

4.  Has MET met its match?

Authors:  Alain Borczuk; Daniel Paucar; Balazs Halmos
Journal:  Ann Transl Med       Date:  2016-03

5.  Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Authors:  Mark M Awad; Giulia C Leonardi; Sasha Kravets; Suzanne E Dahlberg; Alexander Drilon; Sinead A Noonan; D Ross Camidge; Sai-Hong I Ou; Daniel B Costa; Shirish M Gadgeel; Conor E Steuer; Patrick M Forde; Viola W Zhu; Yoko Fukuda; Jeffrey W Clark; Pasi A Jänne; Tony Mok; Lynette M Sholl; Rebecca S Heist
Journal:  Lung Cancer       Date:  2019-05-11       Impact factor: 5.705

Review 6.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:  Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-10-26       Impact factor: 15.609

7.  A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.

Authors:  Linda Mahjoubi; Anas Gazzah; Benjamin Besse; Ludovic Lacroix; Jean-Charles Soria
Journal:  Invest New Drugs       Date:  2016-02-18       Impact factor: 3.850

Review 8.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

9.  Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Authors:  Susan E Jorge; Sol Schulman; Jason A Freed; Paul A VanderLaan; Deepa Rangachari; Susumu S Kobayashi; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-10-31       Impact factor: 5.705

10.  MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Authors:  Rebecca S Heist; Hyo Sup Shim; Shalini Gingipally; Mari Mino-Kenudson; Long Le; Justin F Gainor; Zongli Zheng; Martin Aryee; Junfeng Xia; Peilin Jia; Hailing Jin; Zhongming Zhao; William Pao; Jeffrey A Engelman; A John Iafrate
Journal:  Oncologist       Date:  2016-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.